diluent, or excipient.

[0020] Another example of the disclosure provides methods of treating a hyperproliferative disease or disorder, comprising administering to a mammal in need of such treatment effective amounts of trastuzumab-MCC-DM1 and a chemotherapeutic agent. Trastuzumab-MCC-DM1 and the chemotherapeutic agent may be co-formulated for administration in a combination as a pharmaceutical formulation or they may be administered separately in alternation (alternating, sequential dosages) as a therapeutic combination. In one example, T-DM1 is delivered by infusion and the chemotherapeutic agent is delivered orally.

[0021] Another example of the disclosure provides methods to predict effective drug combinations for in vivo efficacy where the combinations include trastuzumab-MCC-DM1 and an anti cancer, standard-of-care, chemotherapeutic agent. Efficacy data from in vitro cell proliferation and in vivo tumor xenograft experiments are analyzed qualitatively and quantitatively. Quantitative analysis methods may be based on the Chou & Talalay median effect and isobolograms generating a combination index (CI) value to denote synergy, antagonism, or additivity, or on the Bliss Independence ribbon graph deflection.

[0022] Another example of the disclosure is a method of using a therapeutic combination of the disclosure to treat a disease or condition such as cancer, including one modulated by HER2 or KDR9 (VEGF receptor 1) in a mammal.

[0022a] In one example, there is provided a therapeutic combination for use in a method for the treatment of cancer expressing ErbB2, wherein the method comprises administering a therapeutic combination as a combined formulation or by alternation to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1 and a therapeutically effective amount of docetaxel.

[0023] Another example of the disclosure is the use of a therapeutic combination of the disclosure in the preparation of a medicament for the treatment of a disease or condition such as cancer, including one modulated by HER2 or KDR9 (VEGF receptor 1) in a mammal.

[0023a] In another aspect, there is provided use of a therapeutic combination in the manufacture of a medicament for the treatment of breast cancer, wherein the therapeutic combination is to be administered to a mammal as a combined formulation or by alternation, and comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of docetaxel.

[0024] Another example of the disclosure includes articles of manufacture or kits comprising trastuzumab-MCC-DM1, a chemotherapeutic agent, a container, and optionally a package insert or label indicating a treatment.

[0025] Another example of the disclosure includes a method for determining compounds to be used in combination for the treatment of cancer comprising: a) administering a therapeutic combination of trastuzumab-MCC-DM1, and a chemotherapeutic agent selected from a HER2 dimerization inhibitor antibody, an anti-VEGF antibody, 5-FU, carboplatin, lapatinib, ABT-869, docetaxel, GDC-0941, and GNE-390 to an in vitro tumor cell line, and b) measuring a synergistic or non-synergistic effect.

[0026] Additional advantages and novel features of this disclosure shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the

Claims:

1. Use of a therapeutic combination in the manufacture of a medicament for the treatment of breast cancer, wherein the therapeutic combination is to be administered to a mammal as a combined formulation or by alternation, and comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of docetaxel.

2. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of docetaxel are to be administered as a combined formulation.

3. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of docetaxel are to be administered by alternation.

4. The use of claim 3, wherein the mammal is to be administered docetaxel and then subsequently administered trastuzumab-MCC-DM1.

5. The use of claim 2, wherein the therapeutic combination is to be administered at about three week intervals to a human with the breast cancer.

6. The use of any one claims 1 to 5, wherein trastuzumab-MCC-DM1 is to be administered at intervals from about one week to three weeks to a human with the breast cancer.

7. The use of claim 6, wherein the trastuzumab-MCC-DM1 is to be administered no more frequently than every 3 weeks at a dose of 2.4, 3.0 or 3.6 mg/kg intravenously.

8. The use of any one of claims 1 to 7, wherein the amount of trastuzumab-MCC-DM1 and the amount of docetaxel are each from about 1 mg to about 1000 mg and the amount of trastuzumab-MCC-DM1 and the amount of docetaxel are in a ratio of about 1:10 to about 10:1 by weight.

9. The use of any one of claims 1 to 8, wherein the breast cancer is breast cancer expressing ErbB2.

10. The use of any one of claims 1 to 9, wherein the mammal is a HER2 positive patient.

11. The use of any one of claims 1 to 10, wherein the HER2 positive patient has received trastuzumab or lapatinib therapy.